PMID- 30783048
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20190506
IS  - 1938-2650 (Electronic)
IS  - 0001-5547 (Linking)
VI  - 63
IP  - 2
DP  - 2019
TI  - From HPV Infection to Lesion Progression: The Role of HLA Alleles and Host 
      Immunity.
PG  - 148-158
LID - 10.1159/000494985 [doi]
AB  - Persistent high-risk human papillomavirus (HPV) infection has been associated 
      with increased risk for cervical precancerous lesions and cancer. The host's 
      genetic variability is known to play a role in the development of cervical 
      cancer. The human leukocyte antigen (HLA) genes are highly polymorphic and have 
      shown to be important risk determinants of HPV infection persistence and disease 
      progression. HLA class I and II cell surface molecules regulate the host's immune 
      system by presenting HPV-derived peptides to T-cells. The activation of T-cell 
      response may vary depending on the HLA allele polymorphism. The engagement of the 
      T-cell receptor with the HPV peptide-HLA complex to create an active 
      costimulatory signal is essential for the activation of the T-cell response. 
      Functional peptide presentation by both HLA class I and II molecules is needed to 
      activate efficient helper and effector T-cell responses in HPV infection 
      recognition and clearance. Some of these HLA risk alleles could also be used as 
      preventive tools in the detection of HPV-induced cervical lesions and cancer. 
      These HLA alleles, together with HPV vaccines, could potentially offer possible 
      solutions for reducing HPV-induced cervical cancer as well as other HPV-related 
      cancers.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - Paaso, Anna
AU  - Paaso A
AD  - Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, 
      University of Turku, Turku, Finland, aepaas@utu.fi.
AD  - Department of Obstetrics and Gynecology, Turku University Hospital, University of 
      Turku, Turku, Finland, aepaas@utu.fi.
FAU - Jaakola, Anna
AU  - Jaakola A
AD  - Department of Obstetrics and Gynecology, Turku University Hospital, University of 
      Turku, Turku, Finland.
AD  - Department of Obstetrics and Gynecology, Kymenlaakso Central Hospital, Kotka, 
      Finland.
FAU - Syrjanen, Stina
AU  - Syrjanen S
AD  - Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, 
      University of Turku, Turku, Finland.
AD  - Department of Pathology, Turku University Hospital, University of Turku, Turku, 
      Finland.
FAU - Louvanto, Karolina
AU  - Louvanto K
AD  - Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, 
      University of Turku, Turku, Finland.
AD  - Department of Obstetrics and Gynecology, Turku University Hospital, University of 
      Turku, Turku, Finland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190215
PL  - Switzerland
TA  - Acta Cytol
JT  - Acta cytologica
JID - 0370307
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Alleles
MH  - *Disease Progression
MH  - Female
MH  - HLA Antigens/*genetics
MH  - Humans
MH  - *Immunity
MH  - Papillomavirus Infections/*pathology/*virology
MH  - Uterine Cervical Neoplasms/*genetics/pathology/*virology
OTO - NOTNLM
OT  - Cell-mediated immunity
OT  - Cervical cancer
OT  - High-risk genotypes
OT  - Human leukocyte antigen system
OT  - Human papillomavirus
EDAT- 2019/02/21 06:00
MHDA- 2019/05/07 06:00
CRDT- 2019/02/21 06:00
PHST- 2018/10/23 00:00 [received]
PHST- 2018/10/29 00:00 [accepted]
PHST- 2019/02/21 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
PHST- 2019/02/21 06:00 [entrez]
AID - 000494985 [pii]
AID - 10.1159/000494985 [doi]
PST - ppublish
SO  - Acta Cytol. 2019;63(2):148-158. doi: 10.1159/000494985. Epub 2019 Feb 15.